09:56:15 AM

CUE Stock News

CUE - Cue Biopharma Inc

06/07/23 8:00 AM

Nasdaq : CUE

conferences

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will

RHEA-AI

neutral

06/05/23 8:00 AM

Nasdaq : CUE

conferences

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

RHEA-AI

neutral

05/25/23 5:00 PM

Nasdaq : CUE

clinical trial

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three durable stable disease (DSD) responses, two of which have tumor burden reductions of -18% and -24% and

RHEA-AI

neutral

05/15/23 8:00 AM

Nasdaq : CUE

conferences

Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable

RHEA-AI

neutral

05/09/23 4:35 PM

Nasdaq : CUE

earnings

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

RHEA-AI

neutral

05/08/23 8:00 AM

Nasdaq : CUE

conferences

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

RHEA-AI

negative

04/25/23 8:00 AM

Nasdaq : CUE

management

Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

RHEA-AI

very positive

04/12/23 8:00 AM

Nasdaq : CUE

management

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

RHEA-AI

very positive

03/21/23 4:10 PM

Nasdaq : CUE

earnings

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Received U.S. Food and Drug Administration (FDA) acceptance of Investigational New Drug (IND) application for CUE-102 in Wilms’ Tumor 1 (WT1)-expressing cancers and initiated dosing in a Phase 1 dose escalation monotherapy trial at 1mg/kg. Granted FDA Fast Track Designation for CUE-101 for the

RHEA-AI

positive

03/15/23 8:00 AM

Nasdaq : CUE

conferences

Cue Biopharma to Host Business Update Call and Webcast

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

CUE Data

IndustryResearch and Development in Biotechnology
Websitecuebio.com
CeoDaniel Passeri
Security nameCue Biopharma Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2834
Employees52
Tags
- Health Technology
- Biotechnology
Address21 Erie St
StateMassachusetts
CityCambridge
Zip02139-4260
CountryUS
Phone16179492680

About Cue Biopharma Inc

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci